Transcriptomic Profiling Reveals 17β‐Estradiol Treatment Represses Ubiquitin‐Proteasomal Mediators in Skeletal Muscle of Ovariectomized Mice

Georgios Kararigas, Mara C. Ebeling, Gengyun Le, Shaojuan Lai, Chunmei Cui, Qinghua Cui, Dawn A. LoweJournal of Cachexia Sarcopenia and Muscle 2025 · DOI

TL;DR

This study reveals that 17β-estradiol (E2) treatment in ovariectomized mice represses key components of the ubiquitin-proteasomal system in skeletal muscle. This suggests a novel mechanism by which E2 protects against muscle mass and strength loss, highlighting the role of E2 in modulating protein degradation pathways.

What Problem Does This Paper Address?

Menopause is associated with a decline in skeletal muscle mass and strength, and 17β-estradiol (E2) has been implicated as a key regulator of muscle function. While E2's effects on muscle contractility and strength are recognized, the underlying molecular mechanisms, particularly at the transcriptomic level, remain incompletely understood. This paper aims to characterize the global transcriptomic response of skeletal muscle to E2 treatment in ovariectomized mice, specifically investigating whether genes and pathways related to muscle contraction and mass maintenance are differentially expressed. The researchers hypothesize that E2 plays a role in regulating these processes.

Methods

The study employed a multi-pronged approach:

  • Transcriptomic Profiling: Genome-wide expression profiling (microarray) was performed on soleus muscles from ovariectomized (OVX) mice treated with placebo or E2, and from skeletal muscle-specific ERα knockout (skmERαKO) mice and their wild-type littermates (skmERαWT).
  • Quantitative Real-Time PCR (RT-PCR): Used to validate the expression levels of selected candidate genes in both soleus and tibialis anterior (TA) muscles.
  • Western Blotting: Employed to assess protein levels of selected proteasomal subunits and total ubiquitination in TA muscles.
  • Computational Analysis:
    • Microarray Data Analysis: Standard bioinformatics pipelines were used for background correction, normalization, and statistical analysis (limma package) to identify differentially expressed genes. Pathway analysis was conducted using gene set enrichment analysis (GSEA) with the KEGG database.
  • Estrogen Response Element (ERE) Detection: The EREFINDER tool was used to computationally identify potential EREs in the promoter regions of target genes.

Datasets

The microarray data generated in this study has been deposited in the Gene Expression Omnibus (GEO) database under Accession No. GSE134409. No new benchmarks were introduced.

Key Insights and Ideas

  • E2 Represses Protein Degradation Machinery: The most striking finding is that E2 treatment significantly downregulates pathways related to the ubiquitin-proteasomal system, a key cellular machinery responsible for protein degradation. This suggests E2 acts as an anti-catabolic agent in skeletal muscle.
  • ERα is Crucial for E2 Action: Experiments using skmERαKO mice strongly indicate that ERα is essential for E2 to exert its repressive effects on these ubiquitin-proteasomal mediators. This reinforces the established role of ERα as the primary mediator of E2's genomic actions in skeletal muscle.
  • Conserved Effects Across Muscle Types: The observed transcriptomic changes in soleus muscle were largely validated in the tibialis anterior muscle, suggesting that E2's regulatory effects on these pathways are not confined to a single muscle type.
  • Potential ERE Binding Sites: Computational analysis identified putative estrogen response elements (EREs) in the promoter regions of several repressed genes, providing a molecular basis for ERα-mediated transcriptional repression.

Key Results

  • 155 Significantly Regulated Probe Sets: E2 treatment in OVX mice led to 155 significantly regulated probe sets in soleus muscle, with the vast majority (144) being downregulated.
  • Downregulation of Proteasome and Ubiquitin Pathways: Pathway analysis revealed that "Proteasome" and "Ubiquitin-mediated proteolysis" were among the most significantly downregulated pathways in E2-treated mice.
  • Validation of Key Genes: Genes involved in the ubiquitin-proteasomal system (e.g., Fbxw7, Psmb6, Ube2h, Ubxn1) and other relevant genes (Bnip3, Nfkbia) showed reduced expression in TA muscle following E2 treatment, confirmed by RT-PCR.
  • Reduced Protein Levels: Protein levels of proteasome subunits PSMB5 and PSMD11 were significantly lower in E2-treated mice.
  • Decreased Total Ubiquitination: Overall ubiquitination of proteins in TA muscle was modestly but significantly lower in E2-treated mice.
  • ERα Dependence: No significant differences in the expression of selected genes were observed between skmERαKO and skmERαWT mice, and E2 treatment did not alter gene expression in skmERαKO mice, confirming ERα's necessity.

Limitations and Future Work

  • Small Sample Size in Some Experiments: The authors acknowledge that the sample size was relatively small in certain experiments, which might have contributed to the small fold changes observed.
  • Limited Fold Changes: The magnitude of gene expression changes due to E2 was not large, which has been observed in other studies.
  • Proteasome Activity Not Measured: The study did not directly measure proteasome activity, which could provide further functional insights.
  • Variations in E2 Treatment Protocols: Differences in E2 dosing, administration, and duration compared to previous studies might explain some inconsistencies.
  • Future Directions: The authors suggest further studies to investigate the downstream effects of the identified E2 targets and to explore potential sex differences in E2 responses in skeletal muscle. Comparing E2 effects in male and female mice, as well as considering other factors like muscle type, age, and genetic background, would be valuable. Including an ovary-intact control group would also provide a more complete picture.

Summary updated

Abstract

These results suggest that a mechanism whereby E2 protects against losses of skeletal muscle mass and strength is regulation of ubiquitin-proteasomal mediators.
BibTeX
@article{kararigas2025transcriptomic,
  author = {Georgios Kararigas and Mara C. Ebeling and Gengyun Le and Shaojuan Lai and Chunmei Cui and Qinghua Cui and Dawn A. Lowe},
  title = {{Transcriptomic Profiling Reveals 17β‐Estradiol Treatment Represses Ubiquitin‐Proteasomal Mediators in Skeletal Muscle of Ovariectomized Mice}},
  journal = {Journal of Cachexia Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13698},
}
Figure